Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

The activation of lymphocytes by gefitinib treatment has been described. In this phase II pilot trial, we explored the possible synergism between IL-2 and gefitinib for non-small cell lung cancer (NSCLC) treatment. From September, 2003, to November, 2006, 70 consecutive patients with advanced, prog...

Full description

Bibliographic Details
Main Authors:	Melissa Bersanelli, Sebastiano Buti, Roberta Camisa, Matteo Brighenti, Silvia Lazzarelli, Giancarlo Mazza, Rodolfo Passalacqua
Format:	Article
Language:	English
Published:	MDPI AG 2014-09-01
Series:	Cancers
Subjects:	gefitinib interleukin-2 IL-2 lung cancer non-small cell lung cancer NSCLC immunotherapy tyrosine kinase inhibitors TKI
Online Access:	http://www.mdpi.com/2072-6694/6/4/2035

Similar Items

Response to Gefitinib in Pericardial Effusion Due to Lung Cancer
by: Norihiro Kikuchi, et al.
Published: (2003-01-01)

β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2
by: Haibo Cheng, et al.
Published: (2018-11-01)

Drug delivery systems of gefitinib for improved cancer therapy: A review
by: Deepak Nagdiya, et al.
Published: (2023-11-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)

Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer
by: Abdelrahman Y. Sherif, et al.
Published: (2023-01-01)

Gefitinib for Non-small Cell Lung Cancer: A meta Analysis
by: Jiwu GUO, et al.
Published: (2011-04-01)

LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
by: Jung Hee Cho, et al.
Published: (2022-04-01)

Chidamide improves gefitinib treatment outcomes in NSCLC by attenuating recruitment and immunosuppressive function of myeloid-derived suppressor cells
by: Jinjin Shao, et al.
Published: (2024-04-01)

Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases
by: Jianping XU, et al.
Published: (2015-09-01)

Sijunzi Tang improves gefitinib resistance by regulating glutamine metabolism
by: Zhihong Wang, et al.
Published: (2023-11-01)

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression
by: Ren Shengnan, et al.
Published: (2022-11-01)

Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells
by: Xiaolong Huang, et al.
Published: (2017-08-01)

Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
by: Michihito Miyagi, et al.
Published: (2022-12-01)

FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer
by: Jian Li, et al.
Published: (2023-02-01)

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation
by: Tingting Liao, et al.
Published: (2022-09-01)

Enhanced Codelivery of Gefitinib and Azacitidine for Treatment of Metastatic-Resistant Lung Cancer Using Biodegradable Lipid Nanoparticles
by: Ehab M. Elzayat, et al.
Published: (2023-07-01)

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
by: Hu WX, et al.
Published: (2022-04-01)

miR-196a Upregulation Contributes to Gefitinib Resistance through Inhibiting GLTP Expression
by: Bing-Jie Liu, et al.
Published: (2022-02-01)

Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data
by: Melania Brzozowska, et al.
Published: (2019-01-01)

Omega-3 Fatty Acid-Enriched Fish Oil and Selenium Combination Modulates Endoplasmic Reticulum Stress Response Elements and Reverses Acquired Gefitinib Resistance in HCC827 Lung Adenocarcinoma Cells
by: Chien-Huang Liao, et al.
Published: (2020-07-01)

Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+
by: Viola Sacchi
Published: (2011-06-01)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
by: Jun Li, et al.
Published: (2020-02-01)

Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer
by: Moulid Hidayat, et al.
Published: (2019-11-01)

The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis
by: Ainur F. Nasretdinov, et al.
Published: (2022-11-01)

Phosphorylation of AGO2 by TBK1 Promotes the Formation of Oncogenic miRISC in NSCLC
by: Xian Zhao, et al.
Published: (2024-04-01)

Effection and Mechanism of Radiosensitivity of Non-small Cell Lung Cancer Cell Line H358 Following Gefitinib Treatment
by: Jie DENG, et al.
Published: (2011-11-01)

Not COVID-19, Don’t Overlook Pneumocystis in Patients on Gefitinib!
by: Jérémy Barben, et al.
Published: (2021-02-01)

Gefitinib conjugated PEG passivated graphene quantum dots incorporated PLA microspheres for targeted anticancer drug delivery
by: Abhishek Gautam, et al.
Published: (2022-12-01)

CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
by: Jian He, et al.
Published: (2023-03-01)

Cigarette Smoke Induces Gefitinib Resistance in NSCLC Cells  via ROS/Sirt3/SOD2 Pathway
by: Yawan ZI, et al.
Published: (2023-04-01)

ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer
by: Lei Zhao, et al.
Published: (2024-02-01)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wen-Shuo Wu, et al.
Published: (2014-06-01)

Oral Combination Treatment of Gefitinib (Iressa<sup>TM</sup>) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line
by: Jeong-Hoon Oh, et al.
Published: (2023-01-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

Long non-coding RNA prostate cancer-associated transcript 6 inhibited gefitinib sensitivity of non-small cell lung cancer by serving as a competing endogenous RNA of miR-326 to up-regulate interferon-alpha receptor 2
by: Yu Zheng, et al.
Published: (2022-02-01)

HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer
by: Lei Tianyao, et al.
Published: (2022-04-01)

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future
by: Walid Shalata, et al.
Published: (2021-08-01)

Pyogenic Granuloma in a Patient on Gefitinib
by: António Fernandes Massa, et al.
Published: (2016-06-01)

Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC)
by: Camil Ciprian MIRESTEAN, et al.
Published: (2022-09-01)

Aspartames Alter Pharmacokinetics Parameters of Erlotinib and Gefitinib and Elevate Liver Enzymes in Wistar Rats
by: Hajer AlRasheed, et al.
Published: (2022-11-01)